Attain - Abatacept Trial In Treatment of Anti-TNF Inadequate Responders Trademark Details

Attain - Abatacept Trial in Treatment of anti-Tnf Inadequate Responders was registered on Tuesday, February 24, 2009 and is currently owned by Bristol-Myers Squibb Company under the registration number 3581631 . This mark is dead with a status of Cancelled - Section 8. The last case file activity for this mark occured 8 years ago on Friday, September 25, 2015, according to the United State Patent & Trademark Office
Word Mark Attain - Abatacept Trial in Treatment of anti-Tnf Inadequate Responders
Status Dead Registered 710 — Cancelled - Section 8

Current Owner

Bristol-Myers Squibb Company of New York, NY

View all trademarks for Bristol-Myers Squibb Company
Other Trademarks for Bristol-Myers Squibb Company
Serial Number 78416532
Registration Number 3581631
Status Date Friday, September 25, 2015
Filing Date Friday, September 25, 2015
Registration Date Tuesday, February 24, 2009
Attorney Marilyn F. Kelly

Correspondent

Marilyn F. Kelly
Bristol-Myers Squibb Company
Trademark Department
345 Park Avenue
New York NY 10154

Case File Statements

Disclaimer with Predetermined Text "Abatacept Trial in Treatment of anti-Tnf Inadequate Responders"
Goods & Services Medical and Scientific Research, Namely, Conducting Clinical Trials Relating to Pharmaceutical Preparations for Human Use

Classifications

International Class Codes
042 — Class 42 includes mainly services provided by persons, individually or collectively, in relation to the theoretical and practical aspects of complex fields of activities; such services are provided by members of professions such as chemists, physicists, engineers, computer programmers, etc.
U.S. Class Codes 100, 101
Status 2 — Sec. 8 – Entire Registration
Status Date Friday, September 25, 2015
First Use Anywhere Thursday, September 15, 2005
First Use In Commerce Thursday, September 15, 2005
Primary Code 042

You must be signed in to print.

Once signed in, look for the PDF button.